Q1 2024 13F Holders as of 3/31/2024
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
257M
-
Number of holders
-
1473
-
Total 13F shares, excl. options
-
230M
-
Shares change
-
-4.16M
-
Total reported value, excl. options
-
$96.2B
-
Value change
-
-$1.7B
-
Put/Call ratio
-
1.11
-
Number of buys
-
752
-
Number of sells
-
-602
-
Price
-
$418.01
Significant Holders of VERTEX PHARMACEUTICALS INC / MA - Common Stock (VRTX) as of Q1 2024
1,650 filings reported holding VRTX - VERTEX PHARMACEUTICALS INC / MA - Common Stock as of Q1 2024.
VERTEX PHARMACEUTICALS INC / MA - Common Stock (VRTX) has 1,473 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 230M shares
of 257M outstanding shares and own 89.77% of the company stock.
Largest 10 shareholders include Capital World Investors (25.6M shares), VANGUARD GROUP INC (22.7M shares), BlackRock Inc. (22M shares), STATE STREET CORP (12M shares), FMR LLC (10.7M shares), ALLIANCEBERNSTEIN L.P. (7.1M shares), JPMORGAN CHASE & CO (6.02M shares), GEODE CAPITAL MANAGEMENT, LLC (5.81M shares), Capital Research Global Investors (5.74M shares), and JENNISON ASSOCIATES LLC (4.78M shares).
This table shows the top 1473 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.